NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) — Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 8:15 a.m. PT in San Francisco, CA.
The live and archived webcast can be accessed under “Events & Presentations” in the Investor Relations section of the Company’s website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.
About Intra-Cellular Therapies
Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. For more information, please visit www.intracellulartherapies.com.
Contact:
Intra-Cellular Therapies, Inc.
Juan Sanchez, M.D.
Vice President, Corporate Communications and Investor Relations
646-440-9333
Burns McClellan, Inc.
Cameron Radinovic
cradinovic@burnsmc.com
212-213-0006
Government and industry have tried and failed to stem the overdose epidemic for more than…
Financial Assistance From The Assistance Fund Now Available for Eligible People Living With Post-Traumatic Stress…
eClinicalWorks successfully completes UDS+ FHIR® synthetic testing and begins FQHC voluntary testingWESTBOROUGH, Mass.--(BUSINESS WIRE)--eClinicalWorks®, the…
Report Reveals Key Factors Shaping the Healthcare Recruitment and Retention LandscapeNEW YORK, NY / ACCESSWIRE…
Sustained acoustic medicine technology from ZetrOZ Systems eliminates veteran's severe knee pain without surgery or…
Halifax, Nova Scotia--(Newsfile Corp. - March 25, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB:…